Transport and quality control of MHC class I molecules in the early secretory pathway

Current Opinion in Immunology
Sebastian Springer

Abstract

Folding and peptide binding of major histocompatibility complex (MHC) class I molecules have been thoroughly researched, but the mechanistic connection between these biochemical events and the progress of class I through the early secretory pathway is much less well understood. This review focuses on the question how the partially assembled forms of class I (which lack high-affinity peptide and/or the light chain beta-2 microglobulin) are retained inside the cell. Such investigations offer researchers exciting chances to understand the connections between class I structure, conformational dynamics, peptide binding kinetics and thermodynamics, intracellular transport, and antigen presentation.

References

Sep 1, 1991·European Journal of Immunology·J ElvinA Townsend
Jul 27, 1990·Cell·A TownsendA Tse
Feb 14, 1995·Proceedings of the National Academy of Sciences of the United States of America·S DamjanovichT M Jovin
Jul 1, 1993·The Journal of Cell Biology·A VelascoM G Farquhar
Feb 4, 1997·Proceedings of the National Academy of Sciences of the United States of America·J L Campbell, R Schekman
Jun 25, 1998·Current Biology : CB·E A Hughes, P Cresswell
Apr 24, 2002·Immunity·Anthony P WilliamsTim Elliott
Dec 4, 2003·Nature Reviews. Immunology·Jonathan W YewdellJacques Neefjes
Jul 1, 2004·The Journal of Experimental Medicine·Danielle ZernichJames McCluskey
Aug 3, 2004·Proceedings of the National Academy of Sciences of the United States of America·Mark HowarthTim Elliott
Mar 4, 2005·Nature·Joost NeijssenJacques Neefjes
Nov 21, 2007·Cell·R Luke WisemanWilliam E Balch
Mar 14, 2008·Molecular Biology of the Cell·Breanna S IrelandDavid B Williams
Nov 1, 2008·Arthritis and Rheumatism·Helen FussellAntony N Antoniou
Mar 31, 2010·Proceedings of the National Academy of Sciences of the United States of America·Avital LevJonathan W Yewdell
Jun 11, 2010·Annual Review of Biochemistry·Julia Dancourt, Charles Barlowe
Nov 26, 2010·Journal of Cell Science·Esther GhanemSebastian Springer
Mar 9, 2011·Proceedings of the National Academy of Sciences of the United States of America·Wei ZhangPeter Cresswell
Mar 9, 2011·Proceedings of the National Academy of Sciences of the United States of America·Pamela A WearschPeter Cresswell
Mar 10, 2011·Cellular and Molecular Life Sciences : CMLS·Margarita Del ValSilvia Lázaro
Aug 13, 2011·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Malgorzata Anna GarstkaSebastian Springer
Oct 25, 2011·PLoS Computational Biology·Neil DalchauJoern M Werner
Nov 15, 2011·Nature Reviews. Immunology·Jacques NeefjesOddmund Bakke
Mar 31, 2012·Seminars in Immunopathology·Sean O Ryan, Brian A Cobb

❮ Previous
Next ❯

Citations

Jun 21, 2016·Immunological Reviews·Peter van Endert
Mar 1, 2018·Annual Review of Immunology·J Magarian Blander
Feb 1, 2020·Annual Review of Biophysics·Simon Trowitzsch, Robert Tampé
Nov 9, 2016·The Journal of Immunology : Official Journal of the American Association of Immunologists·Randy R Brutkiewicz
Sep 30, 2015·The Journal of Immunology : Official Journal of the American Association of Immunologists·Gerda FleischmannRobert Tampé
Feb 24, 2017·Frontiers in Immunology·Christoph Thomas, Robert Tampé
Jan 23, 2019·Frontiers in Immunology·Sebastian Montealegre, Peter M van Endert
Nov 25, 2020·International Journal of Molecular Sciences·Junki KamiyaKenji Miyado
May 17, 2021·Current Opinion in Immunology·Nouria Jantz-Naeem, Sebastian Springer

❮ Previous
Next ❯

Related Concepts

Related Feeds

CFTR Mutant Structural Therapy

Over 1700 different mutations in the CFTR genes have been shown to cause cystic fibrosis. Here is the latest research on structural therapy for CFTR mutants.